Thomas LeBlanc, MD, Duke Cancer Institute, addresses the ways palliative care and hospice can improve end-of-life outcomes for patients with blood cancers.
Thomas LeBlanc, MD, Duke Cancer Institute, addresses the ways palliative care and hospice can improve end-of-life outcomes for patients with blood cancers.
Transcript
How can improving palliative care and hospice use among patients with blood cancers improve their end-of-life outcomes?
We know that there’s a very clear relationship between receipt of hospice care services at the end of life and quality of end-of-life care. If you look at the national quality forum, there’s several metrics that they pose to measure the quality of care at the end of life and these are applied to all patients with cancer. It’s a yard stick by which we are held basically to measure and attest to the quality of care we are providing among those who die of their disease. When you look at patients with blood cancers compared to those with solid organ tumors, they unfortunately do much worse across all of these end-of-life quality measures. These include things like receipt of chemotherapy in the last two weeks of life, dying in the hospital, spending time in the emergency department in the last month or so of life, utilization of intensive care unit services, things like that, where if you ask an average person and they’d say, "if my time was short I’d really rather be at home, I don’t wanna be in the hospital, I’d rather die at home," and so on.
We know that blood cancer patients do worse in that regard. Some of the data that we presented at this year’s national meeting at the Medicare analysis of leukemia patients shows very clearly that those patients with leukemias in the US who use hospice care services perform dramatically better on all those national quality forum end-of-life measures so they’re far less likely to die in the hospital. They’re much less likely to receive chemotherapy in the last few weeks of life, spend time in the intensive care unit and so on.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More